<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008550</url>
  </required_header>
  <id_info>
    <org_study_id>2018/093/HP</org_study_id>
    <nct_id>NCT04008550</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)</brief_title>
  <acronym>HTP-TAVI</acronym>
  <official_title>Prognostic Impact of the Evolution of Pulmonary Arterial Hypertension 3 Months After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence
      of AS is constantly increasing due to the aging of the population. Several studies have shown
      that pulmonary arterial hypertension (PAH) was common in AS patients referred for TAVI and
      that it was an independent predictor of mortality after TAVI.

      Currently, there is no data in the literature regarding the evolution and prognosis value of
      PAH measured using right heart catheterization (reference method). PAH could either regress
      after TAVI or continue to progress despite the treatment of valvulopathy, resulting in a
      refractory right heart failure that can lead to death.

      The hypothesis of this study is that patients with PAH before TAVI procedure and at the
      3-month follow-up visit (PAH persistence) have an increased risk of cardiovascular mortality
      compared to patients with no PAH at 3 months or having a significant reduction of their PAH
      (PAH regression).

      The aim of the study is to evaluate the prognostic impact of the evolution of PAH after TAVI
      in 424 patients using right heart catheterization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">March 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization for heart failure or death any cause (composite endpoint)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time before the first event (hospitalization or death any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative evolution of the PAH, according to the type of pre-operative PAH</measure>
    <time_frame>Year 2</time_frame>
    <description>PAPm (mean pulmonary arterial pressure) measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of pre-TAVI PAH</measure>
    <time_frame>Year 0</time_frame>
    <description>In percent and according to the type of PAH (pre-TAVI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free survival for heart failure among the 3 types of PAH (pre-TAVI)</measure>
    <time_frame>Year 2</time_frame>
    <description>Occurrence of clinical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis (survival without hospitalization for heart failure) of subjects whose PAH corrected post-TAVI to those who had no pre-TAVI PAH</measure>
    <time_frame>Month 3</time_frame>
    <description>Occurrence of clinical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance between the PAH measurement techniques: echocardiography and right heart catheterization</measure>
    <time_frame>Month 3</time_frame>
    <description>PAPm (mean pulmonary arterial pressure) measurement (Echocardiography or right heart catheterization)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>No Pulmonary Arterial Hypertension before TAVI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention has been done in this group of patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Arterial Hypertension before TAVI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Right Heart Catheterization</intervention_name>
    <description>A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)</description>
    <arm_group_label>Pulmonary Arterial Hypertension before TAVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aortic stenosis

          -  Indication of TAVI

        Exclusion Criteria:

          -  Contra-indication of right heart catheterization

          -  Pregnancy

          -  Persons deprived of their liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Durand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Durand, MD</last_name>
    <phone>+33232888232</phone>
    <email>eric.durand@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine BÃ©ziau-Gasnier, PhD</last_name>
    <phone>+33232886766</phone>
    <email>delphine.beziau-gasnier@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Durand, MD</last_name>
      <phone>+33232888232</phone>
      <email>eric.durand@chu-rouen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI (Transcatheter Aortic Valve Implantation)</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Right Heart Catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

